ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 592

Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis

W Dankers1, Pascal HP de Jong2, S Heil3, S van den Berg3, A Weel4, JMW Hazes5, E Colin6 and Erik Lubberts7, 1Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 2Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Clinincal Chemistry, Erasmus MC, Rotterdam, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands, 5Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 6ZGT Almelo, Deventer, Netherlands, 7Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, etanercept and rheumatoid arthritis (RA), Vitamin D

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Although treatment of rheumatoid arthritis (RA) has significantly improved during the past decades, many patients do not adequately respond or become resistant to current treatments. It is currently unknown why some patients respond well and others do not, and how the response rate could be improved. Vitamin D has strong immunomodulatory properties and it has been shown RA patients have a lower serum 25(OH)D level than healthy individuals. Moreover, vitamin D levels are correlated with disease severity. Interestingly, in vitro studies have shown that vitamin D augments the suppressive effects of etanercept in a simplified model for synovial inflammation. This suggests that vitamin D could improve the therapeutic response to etanercept in RA patients. Therefore we studied if etanercept response is related to serum vitamin D (25(OH)D) levels in RA patients.

Methods: For this study, data were used from the tREACH trial, a multicenter stratified single blinded randomized clinical trial. RA patients, according to the 2010 classification criteria, who started with etanercept within the first 12 months of the study were included in the analysis. Serum vitamin D (25(OH)D) levels were determined at the start of treatment (Tstart) and 3 months later using the LIAISON® 25 OH Vitamin D TOTAL assay . Correlation coefficients between vitamin D levels and the disease activity score (DAS) were calculated. Treatment response was determined with the EULAR response criteria, and difference in response rates was assessed using Chi-Square tests.

Results: 91 patients started etanercept in the first 12 months of the study, of which 24 did not have serum for 25(OH)D measurements at start of treatment and three months later. A total of 67 patients was included, of which 82% was female. At baseline, 45 (67%) and 48 (73%) were positive for rheumatoid factor and anti-citrullinated protein antibodies, respectively. DAS after etanercept treatment was weakly inversely correlated with serum 25(OH)D after treatment (r=-0.29, p=0.02) and the change in 25(OH)D during treatment (r=-0.25, p=0.04). After correcting for DAS and serum 25(OH)D at the start of treatment the aforementioned correlations were still found. Importantly, EULAR response rate was significantly lower in patients who were vitamin D-deficient at the start of treatment (34.6% vs 59.4%) and in patients with decreasing 25(OH)D levels during treatment (39.2% vs 57.7%).

Conclusion: RA patients with a serum 25(OH)D level below 50 nmol/L at the start of etanercept treatment or decreases during treatment have a lower EULAR response rate. Therefore, increasing serum 25(OH)D level in vitamin D deficient patients may be important to achieve optimal effects of TNFα blocking therapy.


Disclosure: W. Dankers, None; P. H. de Jong, None; S. Heil, None; S. van den Berg, None; A. Weel, None; J. Hazes, None; E. Colin, None; E. Lubberts, None.

To cite this abstract in AMA style:

Dankers W, de Jong PH, Heil S, van den Berg S, Weel A, Hazes J, Colin E, Lubberts E. Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/improved-response-to-etanercept-is-associated-with-serum-vitamin-d-levels-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improved-response-to-etanercept-is-associated-with-serum-vitamin-d-levels-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology